BOWMED IBISQUS LIMITED

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

• Turnover

  +21.5%

  £26,372,545 → £32,037,144

• Cash

  -20.1%

  £1,174,123 → £938,612

• Net assets

  +4.1%

  £8,511,379 → £8,862,725

• Employees

  +10%

  10 → 11

• Operating profit

  +33.4%

  £3,453,210 → £4,605,619

• Profit before tax

  +23.8%

  £3,662,712 → £4,535,861

• Wages

  +21.1%

  £743,285 → £900,478

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

IFRS

Reporting scope

Standalone (parent only)

Auditor

Christian Douglass Accountants Limited

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.”

Significant events

• “2024 was challenging with cost increases in the supply chain and significant supplier manufacturing delays. Despite these issues, our business model and experienced team enabled us to achieve an excellent above-budget performance.”
• “2024 saw an increase in revenue & margin of 21% & 38% respectively over 2023 results with a 13% increase in volume supplied year on year.”
• “Total equity has strengthened, but the company's cash position reduced to £900k from £1.2m in 2023 due to changes at the parent company level.”
• “We have published our third carbon reduction plan (CRP) and are committed to achieving net zero by 2050.”
• “The performance of the regulatory authorities has improved for recent licence applications from September 2024, however there is still a backlog in the older applications which are stuck in the system with no obvious solution. This situation directly impacts our core business.”
• “Significant paperwork barriers and regulatory difficulties persist, causing wasted work and physical waste in the supply of medicinal products.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

4

last 12 months

Capital events

0

last 24 months

Officers appointed

0

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.